KRC 01
Alternative Names: H2O2/sodium hyaluronate - KORTUC; KRC-01Latest Information Update: 20 Oct 2022
At a glance
- Originator Kortuc; Okayama University
- Developer Kortuc
- Class Antibacterials; Antiseptics; Disinfectants; Peroxides; Radiosensitisers
- Mechanism of Action Catalase inhibitors; Peroxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer
- Phase I/II Solid tumours
- Preclinical Cervical cancer
Most Recent Events
- 20 Oct 2022 Kortuc enters into R&D agreement with Okayama University for KRC 01
- 17 Oct 2022 Phase-I/II clinical trials in Solid tumours in Japan (Intratumoural, Injection) (Kortuc pipeline; October 2022)
- 17 Oct 2022 Kortuc plans launch for cervical cancer in US and EU markets